Avadel Pharmaceuticals shares new data on LUMRYZ

Avadel Pharmaceuticals announced it will present 11 posters, and one oral presentation, supporting the use of LUMRYZ as a narcolepsy treatment option at SLEEP 2024, the 38th annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society on June 1-5, 2024, in Houston. Approved by the U.S. Food and Drug Administration, FDA, in 2023, LUMRYZ is the first and only extended-release formulation of sodium oxybate and indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness, EDS, in adults with narcolepsy. Highlights from the presentations of new data presented at the meeting include: End-of-study survey data from the RESTORE open-label/switch study demonstrating that patients experienced a high level of satisfaction with once-at-bedtime LUMRYZ. Findings from a human factor study revealing that individuals with narcolepsy, regardless of their prior experience with oxybate treatment, can successfully follow the label instructions for safe use of LUMRYZ. Data showing consistent and acceptable dissolution of LUMRYZ at prescribed doses in various flavored liquids, which may be preferred by some patients as alternatives to water. Post hoc analysis from Avadel’s completed pivotal REST-ON clinical trial that showed treatment with LUMRYZ improved symptoms of EDS and cataplexy in people with narcolepsy regardless of gender. A poster comparing baseline narcolepsy characteristics among three age groups of participants from the REST-ON clinical trial which indicated that baseline measures of EDS were similar among age groups. Findings from a social listening analysis of content posted on MyNarcolepsyTeam, a social network for people with narcolepsy, which concluded that gaining a better understanding of patient experiences and self-management strategies enables sleep specialists to more effectively identify challenges and needs of patients, leading to quicker diagnoses and tailored treatments